International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature

Evan S. Dellon*, Nirmala Gonsalves, J. Pablo Abonia, Jeffrey A. Alexander, Nicoleta C. Arva, Dan Atkins, Stephen E. Attwood, Marcus K.H. Auth, Dominique D. Bailey, Luc Biederman, Carine Blanchard, Peter A. Bonis, Paroma Bose, Albert J. Bredenoord, Joy W. Chang, Mirna Chehade, Margaret H. Collins, Carlo Di Lorenzo, Jorge Amil Dias, Ranjan DohilChristophe Dupont, Gary W. Falk, Cristina T. Ferreira, Adam T. Fox, Robert M. Genta, Thomas Greuter, Sandeep K. Gupta, Ikuo Hirano, Girish S. Hiremath, Jennifer L. Horsley-Silva, Shunji Ishihara, Norihisa Ishimura, Elizabeth T. Jensen, Carolina Gutiérrez-Junquera, David A. Katzka, Paneez Khoury, Yoshikazu Kinoshita, Kara L. Kliewer, Sibylle Koletzko, John Leung, Chris A. Liacouras, Alfredo J. Lucendo, Lisa J. Martin, Emily C. McGowan, Calies Menard-Katcher, David C. Metz, Talya L. Miller, Fouad J. Moawad, Amanda B. Muir, Vincent A. Mukkada, Simon Murch, Quan M. Nhu, Ichiro Nomura, Samuel Nurko, Yoshikazu Ohtsuka, Salvatore Oliva, Rok Orel, Alexandra Papadopoulou, Dhyanesh A. Patel, Robert D. Pesek, Kathryn A. Peterson, Hamish Philpott, Philip E. Putnam, Joel E. Richter, Rachel Rosen, Melanie A. Ruffner, Ekaterina Safroneeva, Philipp Schreiner, Alain Schoepfer, Shauna R. Schroeder, Neil Shah, Rhonda F. Souza, Stuart J. Spechler, Jonathan M. Spergel, Alex Straumann, Nicholas J. Talley, Nikhil Thapar, Yvan Vandenplas, Rajitha D. Venkatesh, Mario C. Vieira, Ulrike von Arnim, Marjorie M. Walker, Joshua B. Wechsler, Barry K. Wershil, Benjamin L. Wright, Yoshiyuki Yamada, Guang Yu Yang, Noam Zevit, Marc E. Rothenberg, Glenn T. Furuta, Seema S. Aceves

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Abstract

Background & Aims: Substantial heterogeneity in terminology used for eosinophilic gastrointestinal diseases (EGIDs), particularly the catchall term “eosinophilic gastroenteritis,” limits clinical and research advances. We aimed to achieve an international consensus for standardized EGID nomenclature. Methods: This consensus process utilized Delphi methodology. An initial naming framework was proposed and refined in iterative fashion, then assessed in a first round of Delphi voting. Results were discussed in 2 consensus meetings, and the framework was updated and reassessed in a second Delphi vote, with a 70% threshold set for agreement. Results: Of 91 experts participating, 85 (93%) completed the first and 82 (90%) completed the second Delphi surveys. Consensus was reached on all but 2 statements. “EGID” was the preferred umbrella term for disorders of gastrointestinal (GI) tract eosinophilic inflammation in the absence of secondary causes (100% agreement). Involved GI tract segments will be named specifically and use an “Eo” abbreviation convention: eosinophilic gastritis (now abbreviated EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). The term “eosinophilic gastroenteritis” is no longer preferred as the overall name (96% agreement). When >2 GI tract areas are involved, the name should reflect all of the involved areas. Conclusions: This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than “eosinophilic gastroenteritis,” and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.

Original languageEnglish
Pages (from-to)2474-2484.e3
JournalClinical Gastroenterology and Hepatology
Volume20
Issue number11
DOIs
StatePublished - Nov 2022

Funding

FundersFunder number
Mapi Research Trust
Novartis Foundation for Biomedical Research
AMGEN
Nutricia, Abbott, and Mead Johnson
International Biometric Society
Office of Rare Diseases Research
Sanofi Genzyme
Receptos
Chugai Pharmaceutical
Eosinophilic Gastrointestinal Disease Researcheres
Takeda Pharmaceuticals U.S.A.
Australian Medical Council
Ferrer
Australian Renewable Energy Agency
Society for the Study of Theology
Rose Pharma
Calypso Biotech SA
School of Public Health, University of California Berkeley
Vifor Pharma
BioGaia
Falk Foundation
Falk Pharma International
Progenity Inc.
Shire
AbbVie
University of California, San Diego
UpToDate
Revolo Biotherapeutics
Shire/Takeda
Mochida Pharmaceutical
Sanofi-Aventis Deutschland
Eli Lilly and Company
Eosinophilic Family Coalition
Zeon Medical Inc.
Mitsubishi Tanabe Pharma Corporation
National Institutes of Health
British Society of Allergy and Clinical Immunology and Chair of Health Advisory Board of Allergy UK
Abbott Laboratories
Sanofi-Aventis AG
Vifor
National Institute of Allergy and Infectious Diseases
Adare Pharmaceuticals
National Health and Medical Research Council
International Foundation for Functional GI Disorders
Anatara Life Sciences
Janssen Pharmaceuticals
Regeneron/Sanofi
Daiichi-Sankyo
Bayer Fund
EosNetwork
JIMRO
Regeneron-Sanofi
LucidDx
Bristol-Myers Squibb
Abonia
GlaxoSmithKline
Sax Institute
Otsuka Pharmaceutical
Avant Foundation
Cincinnati Children's Hospital
Parexel/Calyx
AusEE
EA Pharma Co., Ltd.
National Center for Advancing Translational Sciences
Société des produits Nestlé
Sanofi/Regeneron
Sanofi
Pfizer
Nippon Kayaku
Celgene
AstraZeneca
Sungkyunkwan University School of Medicine
Dr. Falk Pharma
Cadila PharmIncaceuticals
Falk
Medtronic
Medis
Not added21K07833
Nepean Dyspepsia Index2021901692
CEGIRU54 AI117804
American Partnership for Eosinophilic DisordersU2CTR002818

    Keywords

    • Classification
    • Delphi
    • Eosinophilic Gastroenteritis
    • Eosinophilic Gastrointestinal Disease
    • Nomenclature

    Fingerprint

    Dive into the research topics of 'International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature'. Together they form a unique fingerprint.

    Cite this